Skip to main
TRML
TRML logo

TRML Stock Forecast & Price Target

TRML Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 30%
Hold 30%
Sell 0%
Strong Sell 0%

Bulls say

Tourmaline Bio Inc has experienced a significant increase in share value, rising over 30% since its launch, which reflects positive investor sentiment and anticipation of forthcoming data from the TRANQUILITY trial. The firm's estimated market value has reached $1.29 billion, indicating strong financial health and potential for continued growth within the biopharmaceutical market. Moreover, the unique therapeutic potential of its product candidate, pacibekitug, against a backdrop of established safety and efficacy in the IL-6 antibody class, positions the company favorably for future developments and competitive performance in the industry.

Bears say

Tourmaline Bio Inc reported a significant net loss of $73.2 million for the fiscal year 2024, equating to a loss of $2.89 per share, indicating financial instability as the company heavily invests in clinical development. The anticipated topline data from the Phase 2 TRANQUILITY trial in ASCVD, expected in Q2 2025, raises uncertainty about the company's ability to execute commercially, which could adversely influence investor confidence. Additionally, several competitive risks exist, including the potential failure of its key product candidate, pacibekitug, to secure regulatory approval or achieve commercial success, further exacerbating concerns regarding the company's long-term viability.

TRML has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 30% recommend Buy, 30% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tourmaline Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tourmaline Bio Inc (TRML) Forecast

Analysts have given TRML a Buy based on their latest research and market trends.

According to 10 analysts, TRML has a Buy consensus rating as of Sep 9, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $53.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $53.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tourmaline Bio Inc (TRML)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.